ClinicalTrials.gg
Not yet recruitingNCT06544395COVID-19Updated Sep 18, 2025

Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae

An interventional study of Non invasive neuromodulation therapy and Manual therapy in Covid-19 Recurrent, sponsored by Clinica Gema Leon. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Clinica Gema Leon · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Planned enrollment
142nd of 254
104 · median 132
Started
2026
with 1 other
No phase
85 of 401
5 open now
Primary completion
2026-12
later than 18 of 31 live
Registered
384th of 401
by date

Among the 401 studies in COVID-19 with a site in Spain, this one is the 142nd largest by planned enrollment of the 254 interventional ones that give a count, is one of 2 that started in 2026, is one of 85 with no phase, reaches primary completion later than 18 of the 31 other live ones, and was the 384th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is:

- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.

Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).

Participants will:

  • Be evaluated before starting treatment.
  • Be evaluated 3 weeks after.
  • Be evaluated at 5 weeks, or 15 sessions or completion of treatment.
  • Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Read the detailed description

The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware of the consequences it causes both in the respiratory system, musculoskeletal system and in the central and peripheral nervous system.

Likewise, non-invasive neuromodulation acts with a pump of ions, generating endogenous stimuli that modulate the central nervous system.

The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.

To carry out this study, pain was measured with the visual analogue scale. It was also measured the joint amplitude, a muscle assessment with the help of a strength dynamometer, the patient's independence with the Katz index and the functionality of the lower or upper limbs, depending on the affected joint.

03

Conditions studied

  • Covid-19 Recurrent

Browse trials for

Keywords

  • Covid-19
  • Non Invasive Neuromodulation
  • Smell
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between the ages of 18 and 60.
  • Patients with a positive diagnosis of COVID-19.
  • Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases.
  • Patients who signed the .

Exclusion criteria

Exclusion criteria:

  • Patients aged before 18 years and after 60 years.
  • Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases
  • Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Patients receiving non invasive neuromodulation treatment.

    Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive non invasive neuromodulation treatment.

    Device: Non invasive neuromodulation therapy

  • Active comparator
    Patients receiving traditional treatment.

    Patients receiving only traditional therapy. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive treatment of traditional therapy.

    Other: Manual therapy

  • Placebo comparator
    Patients receiving placebo treatment.

    Patients receiving placebo. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).

    Device: Placebo with non invasive neuromodulation

Interventions

  • DeviceNon invasive neuromodulation therapy

    In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks. Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.

  • OtherManual therapy

    Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.

  • DevicePlacebo with non invasive neuromodulation

    In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks. Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off.

06

What researchers measure

Primary outcomes

  1. ad hoc patient survey

    survey of patients about conditions diagnosed during the illness and those they suffer from after infection that are directly related to abnormalities to be assessed.

    Time frame: one month

  2. sex, age, vaccination and number of months with symptoms

    Nominal variables such as sex, age, vaccination and number of months with symptoms

    Time frame: one month

  3. Number of participants with musculoskeletal, respiratory and neurological sequelae of taste and smell after COVID-19

    Time frame: three months

Secondary outcomes

  1. SDOQ-NS questionnaire for social impairments due to loss of smell

    Assess the quality of life impairments of patients with olfactory dysfunction. In a scale of 0 to 3, with higher scores reflecting better olfactory-specific

    Time frame: two months

  2. SF12 Quality of Life Questionnaire

    Assesses the impact of health on an individual's everyday life. Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

    Time frame: two months

  3. Brief Smell Identification Test: Assessment of smell.

    Assesses the ability to recognize familiar odors. A 12-item questionnaire. For each item, a microcapsule containing a familiar odor is scratched with a pencil and placed under the participant's nose. The total score is the number of odors that are correctly recognized. Missing responses are assigned a partial score of 0.25. If more than 2 responses are missing, the entire test is treated as missing.

    Time frame: two months

  4. EuroQoL 5-D scale (validated translation into Spanish) for quality of life.

    Quality of life related to health. Questionaire with two parts: 1. Descriptive system (5 items). Minimum value: 1 (absence of dificulties). Maximum value: 3 (plenty of difficulties). Optimal value: 1. 2. Visual analogical scale (EVA). Minimum value: 0 (worst imaginable state of health). Maximum value: 100 (best imaginable state of health). Optimal value: 100.

    Time frame: two months

  5. upper limb functional index

    It is used to evaluate functional impairment in people with upper extremity musculoskeletal dysfunction. 25 questions assessing the level of difficulty in performing activities of daily living using your upper extremities, including household and work activities, hobbies, lifting a bag of food, washing your scalp, pushing on your hands, driving, etc. Patients respond to each item by circling the number that best describes their level of difficulty.

    Time frame: two months

  6. lower limb functional index

    Valid patient-rated outcome measure to measure lower extremity function. The lower the score the greater the disability. The minimal detectable change is 9 scale points.

    Time frame: two months

  7. Visual analogue scale (VAS), for pain assessment

    Intensity of pain. Minimum value: 0 (absence of pain). Maximum value: 10 (unbearable pain). Optimal value: 0.

    Time frame: two months

  8. Sensory assessment for pain and light touch

    The sensory exam involves evaluation of pain and light touch. Test pain using a sharp object. At minimum, test the shoulders, arms and legs, comparing side to side and proximal to distal areas. In any area where the patient complains of sensory loss or hypersensitivity, more detailed testing may be required. For light touch, uses your fingertips or a wisp of cotton, lightly stroke the skin and determine if the patient feels this symmetrically in all areas tested. At minimum, test the shoulders, arms and legs, comparing side to side and proximal to distal areas.

    Time frame: two months

  9. Sadoul's dyspnea rating scale.

    Respiratory evaluation. Minimum value: 0 (absence of dyspnea). Maximum value: 5 (dyspnea occurs with minimal efforts). Optimal value: 0.

    Time frame: two months

  10. measurement of lung function with spirometry and lung volume testing

    measurement of lung function with spirometry and lung volume testing (measurement of maximum inspiratory and expiratory pressures (Pimax and Pemax, respectively)

    Time frame: three months

07

Study locations

1 site
  • Gema León Physiotherapy and Rehabilitation Clinic
    Córdoba, Andalusia 14011, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 11 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 9, 2024
StartEst.
Jan 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06544395
Lead sponsor
Clinica Gema Leon
Responsible party
GEMA LEÓN BRAVO (Principal Investigator, Clinica Gema Leon) — Principal investigator
First posted
Aug 9, 2024
Start date
Jan 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 18, 2025

Study contacts

GEMA LEÓN BRAVO
Contact
gemafisio@gmail.com
+34667401116
GEMA LEÓN BRAVO
Contact
gemaleonbravo@icloud.com
+34667401116
GEMA LEÓN BRAVO
principal investigator · Departamento de Enfermería, Farmacología y Fisioterapia de la Universidad de Córdoba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion